Apogee Therapeutics Statistics
Total Valuation
APGE has a market cap or net worth of $2.14 billion. The enterprise value is $1.42 billion.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
APGE has 58.09 million shares outstanding. The number of shares has increased by 120.73% in one year.
| Current Share Class | 44.60M |
| Shares Outstanding | 58.09M |
| Shares Change (YoY) | +120.73% |
| Shares Change (QoQ) | +0.80% |
| Owned by Insiders (%) | 2.15% |
| Owned by Institutions (%) | 86.67% |
| Float | 39.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.98 |
| P/TBV Ratio | 2.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.55, with a Debt / Equity ratio of 0.02.
| Current Ratio | 18.55 |
| Quick Ratio | 18.39 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.22% and return on invested capital (ROIC) is -24.41%.
| Return on Equity (ROE) | -33.22% |
| Return on Assets (ROA) | -23.46% |
| Return on Invested Capital (ROIC) | -24.41% |
| Return on Capital Employed (ROCE) | -29.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$929,316 |
| Employee Count | 196 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, APGE has paid $18,000 in taxes.
| Income Tax | 18,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.63% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -20.63% |
| 50-Day Moving Average | 35.43 |
| 200-Day Moving Average | 45.12 |
| Relative Strength Index (RSI) | 55.22 |
| Average Volume (20 Days) | 755,876 |
Short Selling Information
The latest short interest is 8.63 million, so 14.86% of the outstanding shares have been sold short.
| Short Interest | 8.63M |
| Short Previous Month | 8.16M |
| Short % of Shares Out | 14.86% |
| Short % of Float | 22.11% |
| Short Ratio (days to cover) | 10.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -216.87M |
| Pretax Income | -103.55M |
| Net Income | -182.15M |
| EBITDA | -216.68M |
| EBIT | -216.87M |
| Earnings Per Share (EPS) | -$3.30 |
Full Income StatementBalance Sheet
The company has $520.65 million in cash and $11.83 million in debt, giving a net cash position of $719.24 million or $12.38 per share.
| Cash & Cash Equivalents | 520.65M |
| Total Debt | 11.83M |
| Net Cash | 719.24M |
| Net Cash Per Share | $12.38 |
| Equity (Book Value) | 716.79M |
| Book Value Per Share | 12.35 |
| Working Capital | 501.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$171.17 million and capital expenditures -$1.15 million, giving a free cash flow of -$172.33 million.
| Operating Cash Flow | -171.17M |
| Capital Expenditures | -1.15M |
| Free Cash Flow | -172.33M |
| FCF Per Share | -$2.97 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |